Nantahala Capital Management LLC Purchases 1,829,232 Shares of COMPASS Pathways PLC Sponsored ADR $CMPS

Key Points

• Nantahala Capital Management LLC increased its stake in COMPASS Pathways PLC by 182.9% during the first quarter, holding approximately 3.05% of the company with a value of $8,092,000.
• COMPASS Pathways recently reported a quarterly earnings miss, with earnings per share at ($0.38), slightly below the consensus estimate of ($0.37).
• Analysts have set new price targets for COMPASS Pathways, with ratings ranging from "buy" to "overweight" and an average target of $16.29.

Nantahala Capital Management LLC grew its stake in COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 182.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,829,232 shares of the company's stock after purchasing an additional 1,829,232 shares during the quarter. Nantahala Capital Management LLC owned approximately 3.05% of COMPASS Pathways worth $8,092,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of CMPS. Jane Street Group LLC raised its holdings in COMPASS Pathways by 72.7% in the 4th quarter. Jane Street Group LLC now owns 51,815 shares of the company's stock valued at $196,000 after acquiring an additional 21,815 shares during the period. Balyasny Asset Management L.P. acquired a new position in shares of COMPASS Pathways in the fourth quarter valued at approximately $2,458,000. Cubist Systematic Strategies LLC increased its stake in shares of COMPASS Pathways by 205.7% during the fourth quarter. Cubist Systematic Strategies LLC now owns 126,636 shares of the company's stock worth $479,000 after purchasing an additional 85,213 shares during the period. Integral Health Asset Management LLC bought a new position in shares of COMPASS Pathways during the fourth quarter worth approximately $756,000. Finally, Point72 Asset Management L.P. lifted its holdings in COMPASS Pathways by 15.4% during the 4th quarter. Point72 Asset Management L.P. now owns 67,999 shares of the company's stock worth $257,000 after purchasing an additional 9,099 shares during the last quarter. Institutional investors own 46.19% of the company's stock.

COMPASS Pathways Stock Performance

COMPASS Pathways stock traded up $0.04 during midday trading on Friday, hitting $5.14. The company's stock had a trading volume of 2,300,515 shares, compared to its average volume of 1,709,795. COMPASS Pathways PLC Sponsored ADR has a 1-year low of $2.25 and a 1-year high of $7.53. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.82 and a quick ratio of 8.82. The company has a 50-day moving average price of $4.17 and a two-hundred day moving average price of $3.86. The company has a market cap of $493.13 million, a price-to-earnings ratio of -2.79 and a beta of 2.17.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). As a group, sell-side analysts predict that COMPASS Pathways PLC Sponsored ADR will post -2.33 earnings per share for the current year.

Analyst Upgrades and Downgrades

CMPS has been the topic of a number of research reports. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $15.00 price objective on shares of COMPASS Pathways in a report on Friday, August 1st. HC Wainwright reduced their target price on shares of COMPASS Pathways from $45.00 to $40.00 and set a "buy" rating for the company in a research report on Monday, August 4th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $12.00 price target on shares of COMPASS Pathways in a research report on Tuesday, May 27th. Finally, Evercore ISI reiterated an "in-line" rating and issued a $6.00 price objective (down previously from $11.00) on shares of COMPASS Pathways in a research note on Monday, June 23rd. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, COMPASS Pathways has a consensus rating of "Moderate Buy" and an average target price of $16.29.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.